Looking for Steve Daly

Quote





He was the brand leader for Symlin, good guy. BTW, Symlin did not send this company into the crapper. Here is what did it: Top 10 List

1.) Byetta manufacturing in 2006
2.) Unrealistic goals in 2006/2007 (Set by Lilly, of course)
3.) Bad 2nd expansion in 2007. Not needed at all. We should have focused on Endos & high PCP only in larger territories with current sales team. Cost would have been reduced significantly.
4.) Aligning with Lilly in 2008 (territory realignmnets were horrible). People left because of this.
5.) Reject Novo Nordisk leaders at Amylin (you know who they were). Poor leaders.
6.) Revolving door in Byetta marketing from 2006-present
7.) Ex-Pfizer losers in DM/Brand/RD leadership roles: Pfizer has tanked for a reason folks; why bring over losers from a loser organization?
8.) Leadership change from Ginger to Dan: 2007
9.) Cialis co-promotion in 2008. Novo rejects caused this (I hate you Joe).
10.) FDA and how they handled the pancreatitis issue. Poor job that severaly hurt an already struggling company.

That has done us in. You can see that 2007 screwed us up forever...
 


Amylin is falling apart!

I couldn't agree more! I joined Amylin several years ago and loved this company in the beginning. Ginger Graham was fabulous and the company seemed to be heading towards greatness. All of the issues listed above are absolutely true and the changes in upper management has lead to the sinking of this once wonderful ship. The company has degraded itself and it's culture into a micromanaging nightmare with reach and frequency and number of calls per day (and only targeted physicians count)...oh...and by the way, if you don't hit that goal you're fired! They are absolutely weeding out the most tenured reps who make higher bases so that they will have fewer severences to pay when the entire sales force gets laid-off in March after Carl takes over and sells off the company. It's a sad, sad circumstance! I wouldn't recommend this company to anyone right now - even if you are unemployed. You will find yourself stressed out and unhappy. It's become a terrible place to work!
 


ONE OF THE BIGGEST MISTAKES LEADING TO FAILURE was not recognizing Steve Daly's brilliance and making him the VP of Marketing rather then Joe or Onazia. He's surely one of the most gifted leaders who was just ignored. Big mistake.

In fact he's the one that led Symlin to huge increases before some Bozo came up with the idea to add Cialis and make Symlin 3rd.

One of these days someone might figure it out and actually promote this guy to the level he deserves and where Amylin can actually gain from his expertise ---yea, he actually knows what he is doing. Besides he's a great guy too.
 




YUP ---from much market research from HCPs and field and more. Oh, and then a huge increase in scripts after that.
So---you might not have liked the graphics, but pleazzz HCPs dont determin scripts because of graphics --- instead it's content, message, data and what you, the rep tells them. Get over the silly mustard.
 










Anonymous said:
ONE OF THE BIGGEST MISTAKES LEADING TO FAILURE was not recognizing Steve Daly's brilliance and making him the VP of Marketing rather then Joe or Onazia. He's surely one of the most gifted leaders who was just ignored. Big mistake.

In fact he's the one that led Symlin to huge increases before some Bozo came up with the idea to add Cialis and make Symlin 3rd.

One of these days someone might figure it out and actually promote this guy to the level he deserves and where Amylin can actually gain from his expertise ---yea, he actually knows what he is doing. Besides he's a great guy too.[/QUOTE

He's a nice guy, but he's not the guy to have lead the Marketing. Actually, none of the guys we have are sufficient. Six years and we're still trying to define our drugs. It's a shame.
Click to expand...
 






Anonymous said:
Where is Steve and Solomon, they destroyed Symlin. All the budgets wasted on patient programs while doctors never understood the message. What a shame.
Click to expand...

The one factor that caused Symlin to fizzle was the inability to receive the Symlin/basal indication way back when. Byetta cannibalized the Symlin/basal business. The other factor was sales leadership changing the directives of Symlin targets and weighting so many times over the years.
 


I know it's a "no brainer", but I strongly agree that Amylin tanked when Ginger Gramham left and Dan Bradbury took over as President and CEO. The whole culture and management style of the company changed. Amylin went from being "One of the Best Places to Work in San Diego" to zilch.

Amylin was a place employees were happy to go work and excited about the work they did. It became a place where employees held on, endured the day, and lived on hope and the memories of better times. Maybe, just maybe if Bydureon could get approved by the FDA, and the sales did hit the numbers we had been told about so many times over the years, the good times would return. Dan and Orville would retire in glory. The management that would follow them would follow in Ginger's footsteps and Amylin could reach its real potential with the great employees that had worked on her breakthrough drugs.

This was not to be. Because Bydureon's road to approval was paved with lies: Lies to the FDA, Lies to the employees, and Lies to the investors. The entire "we had no idea about the need to do heart study for Bydureon" circus was a lie.

Here is a sample of what I learned from from a few excerpts in a 6/25/12 article by Adam Feuerstein

http://www.thestreet.com/story/1159...-heart-safety-risks-of-key-diabetes-drug.html



"SAN DIEGO (TheStreet) -- Amylin Pharmaceuticals (AMLN_) concealed a study from the U.S. Food and Drug Administration that raised heart safety concerns about its diabetes drug Byetta and then hindered FDA access to the data when the agency discovered its existence, newly released FDA records show."

"Later, Amylin executives lied to investors by failing to disclose that this hidden Byetta heart-safety study played a key role in FDA rejecting the company's follow-on diabetes drug Bydureon, according to these same FDA records."

"One month later, in April 2010, regulators with Health Canada told FDA about a "thorough QT study" of Byetta conducted two years earlier by the company. So-called tQT studies measure the effect a drug has on heart rhythm, an especially important issue to FDA given concerns about the cardiovascular safety of diabetes drugs. This tQT study of Byetta raised significant heart safety concerns for Canadian regulators."

"But Amylin had never told FDA about the tQT study of Byetta and failed to include the troublesome heart-safety data in the initial Byduron approval filing. Amylin withheld these negative safety data even though Amylin agreed to supply FDA with Byetta efficacy and safety data for use in the Bydureon review, FDA's Parks charges in her memo."

How many times did we sit in employee meetings as executives told us how bewildered they were by the request from FDA for the tQT study? How many jobs and lives have been impacted by this lie? Of course, the people who told the lie are doing just fine, thank you. Are you?

Yes, this is old news, but I have to admit it was news to me.
 


Ginger Graham was the heart and soul who created an environment in which the sales force adopted the phrase "challenge science and change lives" as a mission. After Ginger, Amylin was like one great big cosmic balloon with a slow leak.
 


Anonymous said:
I know it's a "no brainer", but I strongly agree that Amylin tanked when Ginger Gramham left and Dan Bradbury took over as President and CEO. The whole culture and management style of the company changed. Amylin went from being "One of the Best Places to Work in San Diego" to zilch.

Amylin was a place employees were happy to go work and excited about the work they did. It became a place where employees held on, endured the day, and lived on hope and the memories of better times. Maybe, just maybe if Bydureon could get approved by the FDA, and the sales did hit the numbers we had been told about so many times over the years, the good times would return. Dan and Orville would retire in glory. The management that would follow them would follow in Ginger's footsteps and Amylin could reach its real potential with the great employees that had worked on her breakthrough drugs.

This was not to be. Because Bydureon's road to approval was paved with lies: Lies to the FDA, Lies to the employees, and Lies to the investors. The entire "we had no idea about the need to do heart study for Bydureon" circus was a lie.

Here is a sample of what I learned from from a few excerpts in a 6/25/12 article by Adam Feuerstein

http://www.thestreet.com/story/1159...-heart-safety-risks-of-key-diabetes-drug.html



"SAN DIEGO (TheStreet) -- Amylin Pharmaceuticals (AMLN_) concealed a study from the U.S. Food and Drug Administration that raised heart safety concerns about its diabetes drug Byetta and then hindered FDA access to the data when the agency discovered its existence, newly released FDA records show."

"Later, Amylin executives lied to investors by failing to disclose that this hidden Byetta heart-safety study played a key role in FDA rejecting the company's follow-on diabetes drug Bydureon, according to these same FDA records."

"One month later, in April 2010, regulators with Health Canada told FDA about a "thorough QT study" of Byetta conducted two years earlier by the company. So-called tQT studies measure the effect a drug has on heart rhythm, an especially important issue to FDA given concerns about the cardiovascular safety of diabetes drugs. This tQT study of Byetta raised significant heart safety concerns for Canadian regulators."

"But Amylin had never told FDA about the tQT study of Byetta and failed to include the troublesome heart-safety data in the initial Byduron approval filing. Amylin withheld these negative safety data even though Amylin agreed to supply FDA with Byetta efficacy and safety data for use in the Bydureon review, FDA's Parks charges in her memo."

How many times did we sit in employee meetings as executives told us how bewildered they were by the request from FDA for the tQT study? How many jobs and lives have been impacted by this lie? Of course, the people who told the lie are doing just fine, thank you. Are you?

Yes, this is old news, but I have to admit it was news to me.
Click to expand...

Ginger got out before things changed; it's not why things changed. The exit strategy, from the beginning, was to build Amylin to the launch of once weekly and then sell. Ginger made a lot of money from the sale of Amylin too. Dan just happened to be the CEO went it all happened. The board was pressured to sell from Icahn; nothing was going to change that fact.
 


Where are Steve Daly and Tom Solomon, heard SD left Affy and went to Cadence and now seems he left Cadence to another non announced company. Solomon seems to be in Tryus, these clowns with healthed crowd have been nothing but abject failure. They never allowed symlin to grow and always blamed everyone but themselves.
 


My daddy says it's not really important where Steve has wound up. Water under the bridge for the company. Daddy says it's always wise to "keep an eye on your future"!

Amy Linn Feldman
 



Write your reply...
Top Bottom
Back
Quote